Up 77% in a month! What's going on with the Mesoblast share price?

This stock has blown the lights out in recent weeks…

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We would all be aware that investing in most ASX shares over 2024 was a lucrative endeavour. After all, the S&P/ASX 200 Index (ASX: XJO) minted around two dozen new all-time record highs last year and rose by a healthy 7.5%. But that gain pales against what the Mesoblast Ltd (ASX: MSB) share price delivered.

Mesoblast shares had a blowout year; no other way to put it. This pharmaceutical company began the year at just 31 cents a share. But by the time December wrapped up, those same shares were going for $3.10. That makes Mesoblast a certified ten-bagger, with investors enjoying a phenomenal return of 900% over the year.

This places the Mesoblast share price amongst the top five performers on the entire All Ordinaries (ASX: XAO) Index for 2024.

A good chunk of those returns have come over just the past month alone. Back in early December, Mesoblast stock was going for $1.66. At today's pricing of $2.94 a share (at the time of writing), that means this company has vaulted 77% higher over the past month alone. The Mesoblast share price has also jumped 162.5% over the past six months.

Check this all out for yourself below:

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

How has the Mesoblast share price rocketed by 73% in a month?

The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas.

As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration (FDA) for its Ryoncil (remestemcel-L) product.

Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease (SR-aGvHD). It is the only therapy that has gained approval for use in children two months and older in the United States.

Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year.

But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards (barring some sporadic profit-taking) ever since.

So the Mesoblast share price is entering 2025 at a notable high. Let's see what the rest of this year brings to this company's jubilant investors.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »